The paradigm of molecular negative hyperselection, beyond RAS and BRAF, identifies metastatic colorectal cancer (mCRC) patients with the greatest benefit from anti-epidermal growth factor receptor (anti-EGFR) agents. Here, BRAF is linked to metastatic colorectal cancer.